Fortress Biotech (FBIO) Issues Quarterly Earnings Results

Fortress Biotech (NASDAQ:FBIO) released its earnings results on Friday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.18, MarketWatch Earnings reports. Fortress Biotech had a negative return on equity of 71.96% and a negative net margin of 47.97%. The company had revenue of $63.69 million for the quarter, compared to analysts’ expectations of $64.88 million.

Shares of FBIO traded up $0.01 on Friday, reaching $1.10. The stock had a trading volume of 194,583 shares, compared to its average volume of 336,941. The stock has a market cap of $59.23 million, a P/E ratio of -0.68 and a beta of 1.46. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.76 and a quick ratio of 2.76. Fortress Biotech has a twelve month low of $0.83 and a twelve month high of $5.54.

A number of research firms recently weighed in on FBIO. ValuEngine cut Fortress Biotech from a “buy” rating to a “hold” rating in a report on Monday, July 16th. HC Wainwright set a $11.00 price target on Fortress Biotech and gave the stock a “buy” rating in a report on Friday, August 10th. Finally, Zacks Investment Research upgraded Fortress Biotech from a “sell” rating to a “hold” rating in a report on Friday, August 10th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Fortress Biotech presently has an average rating of “Buy” and an average price target of $10.67.

COPYRIGHT VIOLATION NOTICE: “Fortress Biotech (FBIO) Issues Quarterly Earnings Results” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at

Fortress Biotech Company Profile

Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.

Featured Story: How Do I Invest in Dividend Stocks

Earnings History for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with's FREE daily email newsletter.

Leave a Reply